|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer显示文摘 | Corcoran Ryan B. Atreya Chloe E. Falchook Gerald S. Kwak Eunice L. Ryan David P. Bendell Johanna C. Hamid Omid Messersmith Wells A. Daud Adil Kurzrock Razelle Pierobon Mariaelena Sun Peng Cunningham Elizabeth Little Shonda Orford Keith Motwani Monica Bai | 2015 | Journal of Clinical Oncology2015，，34： | 2 |
| 2 | CT of Primary Adrenal Lymphoma显示文摘 | Allard JC | 1991 | J Comput Assist Tomogr1991，15，6： | 1 |
| 3 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours:a phase 1 dose-escalation trial 显示文摘 | Falchook GS Long GV Kurzrock R | 2012 | Lancet2012，379，9829： | 1 |
| 4 | BRAF inhibitor dab- rafenib in patients with metastatic BRAF-mutant thyroid cancer 显示文摘 | Falchook GS Millward M Hong D | 2015 | Thyroid2015，25，10： | 1 |
| 5 | Rupture of the biceps tendon:evaluation with MR imaging 显示文摘 | Falchook FS Zlatkin MB Erbacher GE | 1994 | Radiology1994，190，： | 1 |
| 6 | Results of the first-in- human phase I trial assessing MSC2156119J (EMD 1214063) , an oral selective c-Met inhibitor, in patients (pts) with advanced solid tumors显示文摘 | Falchook GS Hang DS Amin HM | 2014 | J Clin Oneol2014，32，15： | 1 |
| 7 | Hep-atosplenic gamma-delta T-cell lymphoma: clinico path-ological features and treatment显示文摘 | FALCHOOK G S VEG A F DANG N H | 2009 | Ann Oncol2009，20，： | 1 |
| 8 | Dabrafenib in patients with melanoma,untreated brain metastases,and other solid tumours:a phase 1 dose-escalation trial显示文摘 | Falchook GS Long GV Kurzrock R | | 0，，9829： | 1 |
| 9 | Relative bio- availability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors 显示文摘 | Falchook GS Venkatakrishnan K Sarantopoulos J et aI | 2015 | Int J Clin Pharmacol Ther2015，53，7： | 1 |
| 10 | Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer 显示文摘 | Falchook GS Naing A Hong DS | 2013 | Oncotarget2013，14，1： | 1 |
| 11 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid turnouts: a phase 1 dose-escalation trial显示文摘 | Falchook GS Long GV Kurzrock R | 2012 | Lancet2012，379，9829： | 1 |
| 12 | CT of Primary Adrenal Lymphoma 显示文摘 | Falchook S Allard JC | 1991 | J Comput AssisiTomogr1991，15，6： | 1 |
| 13 | Safety, pharmacokinetic, pharmacodynamie, and efficacy data for the o- ral MEK inhibitor trametinib: a phase 1 dose-escalation trial显示文摘 | INFANTE JR FECHER LA FALCHOOK GS | 2012 | Lancet Oncol2012，13，8： | 1 |
| 14 | BRAF (V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency 显示文摘 | Hong DS Vence L Falchook G | 2012 | Clin Cancer Res2012，18，8： | 1 |
| 15 | BRAF mutations in advanced cancers: clinical characteristics and outcomes 显示文摘 | EI-Osta H Falchook G Tsimberidou A | 2011 | PLoS One2011，6，25： | 1 |
| 16 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial 显示文摘 | Falchook GS Long GV Kurzrock R | 2012 | Lancet2012，379，9829： | 1 |
| 17 | Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer显示文摘 | Falchook GS Naing A Hong DS | 2013 | Oncotarget2013，4，1： | 1 |
| 18 | Dual HER2inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer显示文摘 | Falchook GS Moulder SL Wheler JJ | 2013 | Ann Oncol2013，24，12： | 1 |
| 19 | CT of primary adrenal lymphama显示文摘 | Falchook FS Allard JC | 1991 | J Comput Assist Tomogr1991，15，6： | 1 |
| 20 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial显示文摘 | Gerald S Falchook Georgina V Long Razelle Kurzrock Kevin B Kim Tobias H Arkenau Michael P Brown Omid Hamid Jeffrey R Infante Michael Millward Anna C Pavlick Steven J O’Day Samuel C Blackman C Martin Curtis Peter Lebowitz Bo Ma Daniele Ouellet Richard F Ke | 2012 | The Lancet . 2012 (9829)2012，，9829： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员